Exploratory clinical trials on safety and bactericidal effect of 222 nm UVC irradiation for healthy human.

Phase 1

• Conditions: Healthy human

• Registration Number: JPRN-UMIN000027449
• Lead Sponsor: Kobe University Hospital

Brief Summary

All subjects had no erythema at all doses. The back of the subject was irradiated at 500 mJ/cm2, and the number of bacterial colonies in the skin swab culture was significantly decreased by 222-nm UVC irradiation. The CPD amount produced in the irradiated region was slightly higher than that of the non-irradiated region.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-07-01
• Study Completion: 2018-04-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1) People with allergies and other drug hypersensitivity 2) Anyone with abnormalities such as dermatitis or trauma at the site to be irradiated with ultraviolet light at the back 3) Those who regularly use external medications or patches at the site to be irradiated with ultraviolet light at the back 4) Those with tattoos at the site to be irradiated with ultraviolet light at the back 5) Pregnant women and those who may be pregnant, or who are breast-feeding 6) Those who have participated in other clinical trials within 4 months 7) Others who are judged inappropriate by the doctor in charge of this trial.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Presence or absence of skin erythema at 24 hours after ultraviolet irradiation of 500 mJ / cm 2 or less.

Secondary Outcome Measures

Name	Time	Method
1. Bacteriocidal effect of skin indigenous bacteria by ultraviolet irradiation. 2. DNA damage in skin cells after ultravioletirradiation. 3. Adverse events.